Mark MacEachern

Mark MacEachern

Auto-generated profile, based on publicly available information

Mark MacEachern

Taubman Health Sciences Library, University of Michigan, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
SWSean A. Woolen
Sean A. Woolen
PSPrasad R. Shankar
Prasad R. Shankar
JGJoel J. Gagnier
Joel J. Gagnier
MMMark P. MacEachern
Mark P. MacEachern
LSLisa Singer
Lisa Singer
MDMatthew S. Davenport
Matthew S. Davenport
Nephrogenic systemic fibrosis (NSF) is a rare, potentially fatal condition caused by iatrogenic gadolinium administration in patients with acute kidney injury or stage 4 or 5 chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m2.1-4 After more than 500 cases of NSF were reported from 1997 to 2007, regulations were adopted to prevent NSF.5 In 2007, the US Food and Drug Administration mandated a black box warning advising avoidance of all gadolinium-containing contrast agents (GBCA) in at-risk patients.5 The label was updated in 2010 to contain recommendations for health care professionals regarding kidney function screening, use of lower-risk GBCAs, and decreasing GBCA dose.6 Such recommendations informed hospital policies and were successful in effectively eliminating the disease.7-9 However, they also resulted in denial or delay of clinically indicated, contrast-enhanced magnetic resonance imaging (MRI) in patients with severe kidney disease, resulting in the undermeasured indirect harms of misdiagnosis and delayed diagnosis.10 In addition, the guidelines were applied to all GBCAs regardless of gadolinium-chelate lability or association with NSF.11,12

16 April 2015 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MPMyria Petrou
Myria Petrou
BDBen A Dwamena
Ben A Dwamena
BFBradley R Foerster
Bradley R Foerster
MMMark P MacEachern
Mark P MacEachern
NBNicolaas I Bohnen
Nicolaas I Bohnen
KFKirk A Frey
Kirk A Frey

22 January 2019 in Clinical Diabetes and Endocrinology
Verified
Journal Article
Open access
PDF file
MTMeng H. Tan
Meng H. Tan
RIRavi Iyengar
Ravi Iyengar
KMKara Mizokami-Stout
Kara Mizokami-Stout
SYSarah Yentz
Sarah Yentz
MMMark P. MacEachern
Mark P. MacEachern
RGRoma Gianchandani
Roma Gianchandani
Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat patients with many advanced solid tumor and hematological malignancies to improve their prognosis. Case reports of their endocrine immune-related adverse events [irAEs]) are increasingly published as more real-world patients with these malignancies are treated with these drugs. They alert physicians of a drug’s AEs (which may change during a drug’s life cycle) and contribute to post-marketing safety surveillance. Using a modified framework of Arksey and O’Malley, we conducted a scoping review of the spectrum and characteristics of ICI-induced endocrinopathies case reports before and after ICIs are marketed. In July 2017, we searched, without date and language restrictions, 4 citation databases for ICI-induced endocrinopathies. We also hand-searched articles’ references, contents of relevant journals, and ran supplemental searches to capture recent reports through January 2018. For this study, a case should have information on type of cancer, type of ICI, clinical presentation, biochemical tests, treatment plus temporal association of ICI initiation with endocrinopathies. Two endocrinologists independently extracted the data which were then summarized and categorized. One hundred seventy nine articles reported 451 cases of ICI-induced endocrinopathies - 222 hypopituitarism, 152 thyroid disorders, 66 diabetes mellitus, 6 primary adrenal insufficiencies, 1 ACTH-dependent Cushing’s syndrome, 1 hypoparathyroidism and 3 diabetes insipidus cases. Their clinical presentations reflect hormone excess or deficiency. Some were asymptomatic and others life-threatening. One or more endocrine glands could be affected. Polyglandular endocrinopathies could present simultaneously or in sequence. Many occur within 5 months of therapy initiation; a few occurred after ICI was stopped. Mostly irreversible, they required long-term hormone replacement. High dose steroids were used when non-endocrine AEs coexisted or as therapy in adrenal insufficiency. There was variability of information in the case reports but all met the study criteria to make a diagnosis. The spectrum of ICI-induced endocrinopathies is wide (5 glands affected) and their presentation varied (12 endocrinopathies). Clinical reasoning integrating clinical, biochemical and treatment information is needed to properly diagnose and manage them. Physicians should be vigilant for their occurrence and be able to diagnose, investigate and manage them appropriately at onset and follow-up.

1 June 2017 in Anesthesiology
Verified
Journal Article
Open access
PDF file
LLLinden O. Lee
Linden O. Lee
BBBrian T. Bateman
Brian T. Bateman
SKSachin Kheterpal
Sachin Kheterpal
TKThomas T. Klumpner
Thomas T. Klumpner
MHMichelle Housey
Michelle Housey
OIon behalf of the Multicenter Perioperative Outcomes Group Investigators
on behalf of the Multicenter Perioperative Outcomes Group Investigators
Background: Thrombocytopenia has been considered a relative or even absolute contraindication to neuraxial techniques due to the risk of epidural hematoma. There is limited literature to estimate the risk of epidural hematoma in thrombocytopenic parturients. The authors reviewed a large perioperative database and performed a systematic review to further define the risk of epidural hematoma requiring surgical decompression in this population. Methods: The authors performed a retrospective cohort study using the Multicenter Perioperative Outcomes Group database to identify thrombocytopenic parturients who received a neuraxial technique and to estimate the risk of epidural hematoma. Patients were stratified by platelet count, and those requiring surgical decompression were identified. A systematic review was performed, and risk estimates were combined with those from the existing literature. Results: A total of 573 parturients with a platelet count less than 100,000 mm–3 who received a neuraxial technique across 14 institutions were identified in the Multicenter Perioperative Outcomes Group database, and a total of 1,524 parturients were identified after combining the data from the systematic review. No cases of epidural hematoma requiring surgical decompression were observed. The upper bound of the 95% CI for the risk of epidural hematoma for a platelet count of 0 to 49,000 mm–3 is 11%, for 50,000 to 69,000 mm–3 is 3%, and for 70,000 to 100,000 mm–3 is 0.2%. Conclusions: The number of thrombocytopenic parturients in the literature who received neuraxial techniques without complication has been significantly increased. The risk of epidural hematoma associated with neuraxial techniques in parturients at a platelet count less than 70,000 mm–3 remains poorly defined due to limited observations.

1 August 2014 in Journal of Periodontology
Verified
Journal Article
Closed access
HCHsun‐Liang Chan
Hsun‐Liang Chan
GLGuo-Hao Lin
Guo-Hao Lin
FSFernando Suarez
Fernando Suarez
MMMark MacEachern
Mark MacEachern
HWHom‐Lay Wang
Hom‐Lay Wang
Background: This systematic review was requested by the Task Force of the American Academy of Periodontology as a follow‐up study of the 2013 report, with an aim to investigate the efficacy of different surgical approaches to treat peri‐implantitis.Methods: A search of four electronic databases from January 1990 to May 2013 was performed. Studies included were human clinical trials published in English that applied surgeries for treating peri‐implantitis. Parameters evaluated included probing depth (PD) reduction, clinical attachment level gain, bleeding on probing (BOP) reduction, radiographic bone fill (RBF), and mucosal recession. The weighted mean (WM) and the 95% confidence interval of the studied parameters were estimated with the random‐effect model.Results: A total of 1,306 studies were initially identified, after reviewing titles, abstracts, and full texts, and 21 articles, 12 of which were case series, were finally included. Four treatment groups were identified: 1) access flap and debridement; 2) surgical resection; 3) application of bone grafting materials; and 4) guided bone regeneration. The mean initial PD ranged from 4.8 to 8.8 mm, with initial BOP ranging from 19.7% to 100%. Short‐term follow‐ups (3 to 63 months) revealed that the available surgical procedures yielded a WM PD reduction of 2.04 (group 2) to 3.16 mm (group 4), or 33.4% to 48.2% of the initial PD. The WM RBF was 2.1 mm for groups 3 and 4.Conclusions: Within the limitation of this systematic review, the application of grafting materials and barrier membranes resulted in greater PD reduction and RBF, but there is a lack of high‐quality comparative studies to support this statement. The results might be used to project treatment outcomes after surgical management of peri‐implantitis.

1 January 2013 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
CHCrystal Holmes
Crystal Holmes
JWJames S Wrobel
James S Wrobel
MEMark P Mac Eachern
Mark P Mac Eachern
BBBlaise R Boles
Blaise R Boles
Peer reviewed article authored by (Holmes C, Wrobel JS, MacEachern MP, Boles BR). Read article or submit your manuscript for publishing.